CA
GSK icon

Clearstead Advisors’s GSK GSK Stock Holding History

Clearstead Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
25,921
+11,038
+74% +$584K 0.01% 472
2026
Q1 		$821K Sell
14,883
-876
-6% -$47.5K 0.01% 580
2025
Q4 		$773K Sell
15,759
-691
-4% -$32.2K 0.01% 539
2025
Q3 		$710K Buy
16,450
+170
+1% +$6.64K 0.01% 539
2025
Q2 		$625K Sell
16,280
-26
-0.2% -$993 0.01% 554
2025
Q1 		$632K Sell
16,306
-901
-5% -$33K 0.01% 524
2024
Q4 		$582K Sell
17,207
-665
-4% -$23.9K 0.01% 536
2024
Q3 		$731K Sell
17,872
-559
-3% -$22.9K 0.01% 487
2024
Q2 		$710K Buy
18,431
+10,925
+146% +$460K 0.01% 468
2024
Q1 		$339K Sell
7,506
-168
-2% -$6.93K 0.02% 381
2023
Q4 		$284K Sell
7,674
-8,292
-52% -$298K 0.02% 408
2023
Q3 		$579K Buy
15,966
+7,978
+100% +$283K 0.02% 387
2023
Q2 		$285K Buy
7,988
+1,818
+29% +$65.2K 0.02% 382
2023
Q1 		$220K Buy
6,170
+2,575
+72% +$90.1K 0.02% 377
2022
Q4 		$126K Sell
3,595
-609
-14% -$20.3K 0.01% 456
2022
Q3 		$124K Sell
4,204
-1,126
-21% -$42.7K 0.01% 434
2022
Q2 		$290K Buy
5,330
+1,389
+35% +$76.7K 0.02% 326
2022
Q1 		$215K Buy
3,941
+311
+9% +$16.9K 0.01% 394
2021
Q4 		$200K Sell
3,630
-3,136
-46% -$163K 0.01% 389
2021
Q3 		$323K Buy
6,766
+1,267
+23% +$63.6K 0.02% 302
2021
Q2 		$274K Buy
5,499
+3,353
+156% +$161K 0.02% 304
2021
Q1 		$96K Buy
2,146
+220
+11% +$9.99K 0.01% 446
2020
Q4 		$89K Buy
1,926
+172
+10% +$7.9K 0.01% 438
2020
Q3 		$83K Sell
1,754
-1,949
-53% -$97.7K 0.01% 395
2020
Q2 		$189K Hold
3,703
– – 0.02% 272
2020
Q1 		$175K Sell
3,703
-515
-12% -$27.5K 0.03% 253
2019
Q4 		$248K Buy
+4,218
New +$235K 0.03% 246

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Clearstead Advisors's GSK Position: Q2 2026 in Review

Clearstead Advisors increased its GSK (GSK) stake by 74% in Q2 2026, buying an estimated $584K and bringing the position to 25,921 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #472.

Clearstead Advisors first reported a position in GSK in Q4 2019 and has held it in 27 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Clearstead Advisors held 25,921 shares of GSK worth $1.36M as of Q2 2026.
  • Clearstead Advisors bought 11,038 GSK shares in Q2 2026, an estimated $584K.
  • GSK made up 0.01% of Clearstead Advisors's portfolio in Q2 2026, its #472 holding.
  • Clearstead Advisors first reported a position in GSK in Q4 2019 and has held it in 27 quarters since.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.